. Author manuscript; available in PMC: 2010 May 1.

Published in final edited form as: Eur J Nucl Med Mol Imaging. 2010 Jan 13;37(5):884–895. doi: 10.1007/s00259-009-1351-2

Table 2.

Mean±standard deviation (range) of the ¹³¹I ODpA, the ¹³¹I residence time (τ), and of the volume (V_gl) derived from the ¹²⁴I PET(/CT) (n=10) and ¹³¹I GCS/US dosimetry (n=9) approaches as well as their relative mean deviations (Δ) between the two approaches and the corresponding significance levels (p)^a

	Submandibular gland		Parotid gland
	PET(/CT)	GCS/US^b	PET(/CT)	GCS/US^b
ODpA (Gy/GBq)	0.32±0.13 (0.18–0.55)	0.40±0.13 (0.19–0.60)	0.31±0.10 (0.13–0.46)	0.26±0.09 (0.14–0.40)
	Δ=+25%, p=0.206		Δ=−16%, p=0.270
τ (min)	2.12±1.43 (0.84–4.61)	2.30±0.62 (1.48–3.06)	5.11±2.66 (2.09–10.34)	2.38±0.78 (1.43–3.60)
	Δ=+8%, p=0.153		Δ=−53%, p=0.005
V_gl (ml)	12.0±4.3 (4.7–18.9)	12.1±6.0 (4.5–25.3)	29.4±8.5 (15.6–47.3)	18.6±4.7 (8.7–24.0)
	Δ=+1%, p=0.713		Δ=−37%, p=0.004

Ranges are explicitly given although the data are all normally distributed except for the PET(/CT)-derived residence times of the submandibular gland. Mean relative deviation (Δ) is given in percentage of the PET(/CT)-based values

Data were taken from reference [4] using the data of the low-activity group only. ODpAs were re-calculated using Eq. 4. Data are all normally distributed